SAGE Therapeutics Inc (NASDAQ:SAGE) has recently been included in a filing by Jacob Gottlieb‘s Visium Asset Management. According to the 13G filing with the US Securities and Exchange Commission, Visium currently owns 5.9% of SAGE Therapeutics, which represent around 5.9% of the company’s outstanding stock. This compares with the 902,948 shares that Visium disclosed in its last 13F filing, for the third quarter of 2015.
You can access the original SEC filing by clicking here.
Ownership Summary Table
|Name||Sole Voting Power||Shared Voting Power||Sole Dispositive Power||Shared Dispositive Power||Aggregate Amount Owned Power||Percent of Class|
|Visium Asset Management,||1,893,009||1,893,009||1,893,009||5.9%|
Page 1 of 11 SEC Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Under the Securities Exchange Act of 1934
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
February 1, 2016
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to
designate the rule pursuant to which this Schedule is filed:
x Rule 13d-1(b)**
x Rule 13d-1(c)**
¨ Rule 13d-1(d)
|*||The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information |
which would alter disclosures provided in a prior cover page.
|**||This Schedule is being filed pursuant to Rule 13d-1(b) with respect to Visium Asset Management, LP, JG Asset, LLC and Jacob Gottlieb, and pursuant to Rule 13d-1(c) with respect to certain advisory clients of Visium |
Asset Management, LP.
The information required on the remainder of this cover page shall not be deemed to be filed for the
purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).